FCGR1A and cancer: However, our recent findings, i.e., the identification of CD64+ monocytic progenitors, such as rGMP, cMoP and pre-monocytes, provided an opportunity to reconsider and review the utility of anti-CD64 ADC for anti-cancer therapy and side effects on hematopoiesis.